AKT3
Top View
- Bioinformatics Analysis of the CDK2 Functions in Neuroblastoma
- Oncomine Comprehensive Assay V3 Empower Your Oncology Research with Proven Ion Torrent Technology
- 3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma
- Lestaurtinib
- The Clinicopathological Characteristics and Genetic Alterations of Signet-Ring Cell Carcinoma in Gastric Cancer
- Summary of ACMG-AMP Criteria for AKT3, MTOR, PIK3CA and PIK3R2
- BRAF Inhibitor Resistance Mediated by the AKT Pathway in an Oncogenic BRAF Mouse Melanoma Model
- AKT3 AKT3 Kinase Assay
- Hereditary Cancer Panel Descriptions
- AKT As a Therapeutic Target for Cancer Mengqiu Song1,2, Ann M
- The Absence of a Ca2+ Signal During Mouse Egg Activation Can Affect
- Oncogenic Transformation Induced by Membrane-Targeted Akt2 and Akt3
- Akt/Mtor Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–Like Growth Factor I Receptor Monoclonal Antibody
- MDM2 Restrains Estrogen-Mediated AKT Activation by Promoting TBK1-Dependent HPIP Degradation
- Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
- Targetable Fusion Genes in Breast Cancer
- Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer Casey Stottrup, Tiffany Tsang, and Y
- Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition